Physician profile
Anthony D Martinez
NPI 1598712754
$1,617,435.30
in general payments reported to CMS, 2019-2025
21 companies · $385K in 2025
The $385K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259K · 2020: $114K · 2021: $196K · 2022: $219K · 2023: $167K · 2024: $278K · 2025: $385K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $576K · Consulting Fee: $115K · Travel and Lodging: $92K · Food and Beverage: $20K · Honoraria: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $576,354.44 |
| Consulting Fee | $115,075.00 |
| Travel and Lodging | $92,458.62 |
| Food and Beverage | $20,141.38 |
| Honoraria | $15,840.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $761,207.82 | 2019-2025 | |
| Gilead Sciences, INC. | $548,559.86 | 2019-2025 | Epclusa, Descovy, Yeztugo |
| Madrigal Pharmaceuticals | $231,611.97 | 2024-2025 | Rezdiffra, Resmetirom |
| Braeburn INC. | $17,396.12 | 2024-2025 | Brixadi |
| Novo Nordisk INC | $14,933.55 | 2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $11,249.08 | 2025 | Iqirvo |
| Cepheid | $10,000.00 | 2024-2025 | Genexpert |
| Eisai INC. | $9,598.65 | 2019-2022 | |
| Vbi Vaccine (Delaware) INC. | $4,310.00 | 2022-2023 | Prehevbrio |
| Roche Diagnostics Corporation | $3,885.00 | 2023 | |
| Dova Pharmaceuticals | $3,313.36 | 2019 | |
| Intercept Pharmaceuticals, INC. | $605.51 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $487.30 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Orexo US, INC. | $114.48 | 2021-2025 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $44.14 | 2019-2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Theratechnologies INC. | $40.90 | 2022 | |
| Sirtex Medical INC | $25.66 | 2019 | |
| Viiv Healthcare Company | $19.38 | 2024 | Cabenuva |
| Celgene Corporation | $16.88 | 2021 | |
| Nevro Corp. | $15.64 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.